Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides.
HBV genotype G
HBc
SARS-CoV-2 epitopes
VLP
immunogenicity
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
23
12
2023
revised:
22
02
2024
accepted:
29
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
Virus-like particles (VLPs) offer an attractive possibility for the development of vaccines. Recombinant core antigen (HBc) of Hepatitis B virus (HBV) was expressed in different systems, and the
Identifiants
pubmed: 38543900
pii: vaccines12030267
doi: 10.3390/vaccines12030267
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Latvian Council of Science
ID : lzp- 2021/1-0059